Home HOME Neoplasma 2021 Neoplasma Vol.68, No.4, p.852–860, 2021

Journal info

6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.68, No.4, p.852–860, 2021

Title: Metabolomic profiling of blood plasma of patients with lung cancer and malignant tumors with metastasis in the lungs showed similar features and promising statistical discrimination against controls
Author: Miroslava Sarlinova, Eva Baranovicova, Michaela Skalicanova, Anton Dzian, Martin Petras, Jan Lehotsky, Dagmar Kalenska, Peter Racay, Tatiana Matakova, Erika Halasova

Abstract: Targeting metabolomic pathways is a promising strategy for cancer treatment. Alterations in the metabolomic state have also an epigenetic impact making the metabolomic studies even more interesting. We explored metabolomic changes in blood plasma of patients with primary and secondary lung cancer and tried to explore their origin. We also applied a discrimination algorithm on the data. In the study, blood samples from 132 patients with primary lung cancer, 47 with secondary lung cancer, and 77 subjectively healthy subjects without any cancer history were used. The samples were measured by NMR spectroscopy. PCA and PLSDA analyzes did not distinguish between patients with primary and secondary lung tumors. Accordingly, no significantly changed levels of plasmatic metabolites were found between these groups. When comparing with healthy controls, significantly increased glucose, citrate, acetate, 3-hydroxybutyrate, and creatinine balanced with decreased pyruvate, lactate, alanine, tyrosine, and tryptophan were found as a common feature of both groups. Metabolomic analysis of blood plasma showed considerable proximity of patients with primary and secondary lung cancer. The changes observed can be partially explained as cancer-derived and also as changes showing ischemic nature. Random Forrest discrimination based on the relative concentration of metabolites in blood plasma performed very promising with AUC of 0.95 against controls; however noticeable parts of differencing metabolites are overlapping with those observed after ischemic injury in other studies.

Keywords: lung cancer; NMR metabolomics; blood plasma
Published online: 27-Apr-2021
Year: 2021, Volume: 68, Issue: 4 Page From: 852, Page To: 860

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.